Dr John Skidmore

John Skidmore is a chemist by training, receiving a BA and DPhil from the University of Oxford. Following a post doc at the University of Liverpool, John joined GSK where he worked as a medicinal chemist and project leader in the pain and neurodegeneration therapeutic areas contributing to the discovery of a number of development candidates. In 2010 John moved to the University of Cambridge, where, funded through the Wellcome Trust’s Seeding Drug Discovery scheme, he led a number of protein-protein interaction inhibitor projects in the oncology therapeutic area working with Chris Abell, Tom Blundell and others. In 2015 John moved within the University, to his present position as the CSO of the ALBORADA Cambridge Drug Discovery Institute where he leads a group translating academic research into new treatments for the diseases that cause dementia.